
Oragenics Receives Ethics Approval for Phase IIa Concussion Trial in Australia
Oragenics Inc. has secured Australian ethics approval to begin a Phase IIa clinical trial for its intranasal neurosteroid drug candidate ONP-002 to treat concussion, marking a significant step toward addressing the unmet medical need for traumatic brain injury treatments.
Read full story


























